Your session is about to expire
← Back to Search
Other
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19 (SPRINT Trial)
Phase 2
Waitlist Available
Research Sponsored by Enanta Pharmaceuticals, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 through day 33
Summary
This trial is testing a new medication called EDP-235. It is aimed at adults who have mild or moderate COVID-19 but are not in the hospital. The medication works by stopping the virus from multiplying, which can help reduce symptoms and speed up recovery.
Eligible Conditions
- Coronavirus
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1 through day 33
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 through day 33
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Change From Baseline in COVID-19 Signs/Symptom
Side effects data
From 2023 Phase 2 trial • 231 Patients • NCT056167281%
Hepatotoxicity
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
EDP-235 200mg
EDP-235 400mg
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: EDP-235 400mgExperimental Treatment1 Intervention
Once a day orally for 5 days
Group II: EDP-235 200mgExperimental Treatment1 Intervention
Once a day orally for 5 days
Group III: PlaceboPlacebo Group1 Intervention
Once a day orally for 5 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
EDP-235
2022
Completed Phase 2
~370
Find a Location
Who is running the clinical trial?
Enanta Pharmaceuticals, IncLead Sponsor
40 Previous Clinical Trials
2,890 Total Patients Enrolled